187 related articles for article (PubMed ID: 38059556)
1. Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene.
Bhat-Nakshatri P; Khatpe AS; Chen D; Batic K; Mang H; Herodotou C; McGuire PC; Xuei X; Erdogan C; Gao H; Liu Y; Sandusky G; Storniolo AM; Nakshatri H
Cancer Res Commun; 2024 Jan; 4(1):38-54. PubMed ID: 38059556
[TBL] [Abstract][Full Text] [Related]
2. Spatial Transcriptomics Suggests That Alterations Occur in the Preneoplastic Breast Microenvironment of BRCA1/2 Mutation Carriers.
Caputo A; Vipparthi K; Bazeley P; Downs-Kelly E; McIntire P; Duckworth LA; Ni Y; Hu B; Keri RA; Karaayvaz M
Mol Cancer Res; 2024 Feb; 22(2):169-180. PubMed ID: 37878345
[TBL] [Abstract][Full Text] [Related]
3. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
4. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
[TBL] [Abstract][Full Text] [Related]
5. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
6. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
7. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Zhang J; Sun J; Chen J; Yao L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2016 Aug; 158(3):455-62. PubMed ID: 27393621
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Cecener G; Sabour Takanlou L; Sabour Takanlou M; Egeli U; Eskiler GG; Aksoy S; Unal U; Tezcan H; Eryilmaz IE; Gokgoz MS; Tunca B; Cubukcu E; Evrensel T; Cetintas S; Tasdelen I
Cancer Genet; 2020 Jan; 240():23-32. PubMed ID: 31706072
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Stevens KN; Wang X; Fredericksen Z; Pankratz VS; Greene MH; Andrulis IL; Thomassen M; Caligo M; ; Nathanson KL; Jakubowska A; Osorio A; Hamann U; Godwin AK; Stoppa-Lyonnet D; Southey M; Buys SS; Singer CF; Hansen TV; Arason A; Offit K; Piedmonte M; Montagna M; Imyanitov E; Tihomirova L; Sucheston L; Beattie M; ; ; Neuhausen SL; ; Szabo CI; ; Simard J; Spurdle AB; Healey S; Chen X; Rebbeck TR; Easton DF; Chenevix-Trench G; Antoniou AC; Couch FJ
Breast Cancer Res Treat; 2012 Nov; 136(1):295-302. PubMed ID: 23011509
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
[TBL] [Abstract][Full Text] [Related]
14. PML protein expression in hereditary and sporadic breast cancer.
Plevová P; Bouchal J; Fiurásková M; Foretová L; Navrátilová M; Zapletalová J; Curík R; Kubala O; Prokop J; Kolár Z
Neoplasma; 2007; 54(4):263-8. PubMed ID: 17822314
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
17. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Antoniou AC; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; McGuffog L; Lee A; Barrowdale D; Healey S; Sinilnikova OM; Caligo MA; Loman N; Harbst K; Lindblom A; Arver B; Rosenquist R; Karlsson P; Nathanson K; Domchek S; Rebbeck T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Złowowcka-Perłowska E; Osorio A; Durán M; Andrés R; Benítez J; Hamann U; Hogervorst FB; van Os TA; Verhoef S; Meijers-Heijboer HE; Wijnen J; Gómez Garcia EB; Ligtenberg MJ; Kriege M; Collée JM; Ausems MG; Oosterwijk JC; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Jacobs C; Eeles R; Adlard J; Davidson R; Cole T; Cook J; Paterson J; Douglas F; Brewer C; Hodgson S; Morrison PJ; Walker L; Rogers MT; Donaldson A; Dorkins H; Godwin AK; Bove B; Stoppa-Lyonnet D; Houdayer C; Buecher B; de Pauw A; Mazoyer S; Calender A; Léoné M; Bressac-de Paillerets B; Caron O; Sobol H; Frenay M; Prieur F; Ferrer SU; Mortemousque I; Buys S; Daly M; Miron A; Terry MU; Hopper JL; John EM; Southey M; Goldgar D; Singer CF; Fink-Retter A; Tea MK; Kaulich DU; Hansen TV; Nielsen FC; Barkardottir RB; Gaudet M; Kirchhoff T; Joseph V; Dutra-Clarke A; Offit K; Piedmonte M; Kirk J; Cohn D; Hurteau J; Byron J; Fiorica J; Toland AE; Montagna M; Oliani C; Imyanitov E; Isaacs C; Tihomirova L; Blanco I; Lazaro C; Teulé A; Valle JD; Gayther SA; Odunsi K; Gross J; Karlan BY; Olah E; Teo SH; Ganz PA; Beattie MS; Dorfling CM; van Rensburg EU; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Schäfer D; Caldes T; de la Hoya M; Nevanlinna H; Muranen TA; Lespérance B; Spurdle AB; Neuhausen SL; Ding YC; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Bonanni B; Bernard L; Dolcetti R; Papi L; Ottini L; Radice P; Greene MH; Loud JT; Andrulis IL; Ozcelik H; Mulligan AU; Glendon G; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Chenevix-Trench G; Couch FJ; Simard J; Easton DF; ; ; ; ;
Breast Cancer Res; 2012 Feb; 14(1):R33. PubMed ID: 22348646
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
Yao L; Sun J; Zhang J; He Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2016 Apr; 156(3):441-445. PubMed ID: 27033093
[TBL] [Abstract][Full Text] [Related]
19. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME; Chappuis PO; Satagopan J; Wong N; Boyd J; Goffin JR; Hudis C; Roberge D; Norton L; Bégin LR; Offit K; Foulkes WD
Breast Cancer Res; 2004; 6(1):R8-R17. PubMed ID: 14680495
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the preneoplastic breast microenvironment of
Caputo A; Vipparthi K; Bazeley P; Downs-Kelly E; McIntire P; Ni Y; Hu B; Keri RA; Karaayvaz M
bioRxiv; 2023 May; ():. PubMed ID: 37292816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
